Understanding Telix, page-1195

this Starlite 1 and Starlite 2
must be nearabout

think i saw H2 2024, not sure if that's 1 or 2 though

too many cakes baking .....


Merck and Telix are continuing the initial scientific collaboration to further exploreand optimise the combination of TLX250 or other next-generation targeted radiationtherapy candidates with Merck's DDRi compounds in preclinical studies. About TLX250 TLX250 ((177) Lu-DOTA-girentuximab) is an antibody-based therapeutic platform thattargets CAIX, a cell surface protein that is highly expressed in several human cancers,and is currently the subject of the STARLITE-1 (ClinicalTrials.gov Identifier:NCT05663710) and STARLITE-2 (NCT05239533) studies in combination with immunotherapy.([2])High CAIX tumour expression is generally correlated with poor prognosis. Telix's companion investigational diagnostic imaging agent TLX250-CDx ((89)Zr-DFO-girentuximab) was the subject of a successful global Phase III trial (ZIRCONtrial, NCT03849118), which completed enrolment and reported positive top-line data during2022.([3]) Analyses of primary endpoints and key secondary endpoints of the ZIRCON trialwere presented to the medical community for the first time at ASCO GU on 18 February2023.([4]) TLX250-CDx is currently being investigated in the Phase II STARBURST study(ClinicalTrials.gov Identifier: NCT05563272) exploring CAIX expression in patients with adiverse range of solid tumours for potential diagnostic and therapeuticapplications.([5]) About Telix Pharmaceuticals Limited